Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs

[Display omitted] Venetoclax is a small molecule inhibitor of BCL-2 used in the treatment of acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL). Recent postmarketing studies of ibrutinib, another small molecule inhibitor, suggested that these agents may predispose to opportunist...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2024-02, Vol.8 (4), p.857-866
Hauptverfasser:	Prosty, Connor, Katergi, Khaled, Nguyen, Alex, Luo, Owen Dan, Sorin, Mark, Cherniak, Vladimir, Sebag, Michael, Demir, Koray, McDonald, Emily G., Lee, Todd C., Cheng, Matthew P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bridged Bicyclo Compounds, Heterocyclic Communicable Diseases Febrile Neutropenia Hematologic Neoplasms - complications Hematologic Neoplasms - drug therapy Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Myeloid, Acute - drug therapy Sulfonamides Systematic Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!